Insulin Agents Flashcards

1
Q

what are glucose dependent insulin agents

A

GLP-1 agonists, DPP-4 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are glucose independent insulin agents

A

sulfonylurea, meglitinides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the moa of glucose dependent agents

A

Insulin secretion is stimulated by elevated blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the moa of glucose independant agents

A

Insulin is secreted regardless of the blood glucose level, even if blood glucose levels are low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is the moa of Sulfonylureas

A

Block ATP-sensitive potassium channels of the pancreatic β cells → depolarization of the cell membrane → calcium influx → insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are first generation Sulfonylureas

A

Chlorpropamide
Tolbutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are second generation Sulfonylureas

A

Glyburide
Glimepiride
Glipizide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are side effects of Sulfonylureas

A

hypoglycaemia
weight gain
agranulocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what interactions are common with Sulfonylureas

A

using biguanides can cause increase in cardiovascular diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are types of meglitinides

A

Nateglinide
Repaglinide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the moa of meglitinides

A

Block ATP-sensitive potassium channels of the pancreatic β cells → depolarization of the cell membrane → calcium influx → insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what side effects of meglitinides

A

Risk of hypoglycemia
Weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are contraindications of Sulfonylureas

A

cardiovascular diseases
obesity
renal failure
liver failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what contraindications when using meglitinides

A

renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are drug interactions with meglitinides

A

Sulfonylureas: ↑ risk of hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are types of DPP4-inhibitors

A

Saxagliptin
Sitagliptin
Linagliptin

17
Q

what is the moa of DPP4-inhibitors

A

Inhibit GLP-1 degradation → ↑ glucose-dependent insulin secretion

18
Q

what are side effects of DPP4-inhibitors

A

Gastrointestinal symptoms
Pancreatitis
Nasopharyngitis, upper respiratory tract infection
Headache, dizziness
Arthralgia
Edema

19
Q

what are contraindications of DPP4

A

Liver failure
Moderate to severe renal failure

20
Q

what are drug interations of DPP4

A

CYP3A4/5 inhibitors: ↑ concentration of saxagliptin [1]

21
Q

what are types of GLP-1

A

Exenatide
Liraglutide
Albiglutide
Semaglutide

22
Q

what are the MOA of GLP-1

A

Stimulate the GLP-1 receptor directly

23
Q

what are the side effects of GLP-1

A

Risk of pancreatitis and possibly pancreatic cancer
Nausea

24
Q

what are drug interactions of GLP-2

A

warfarin

25
Q

what are contraindications of sulfonyreus

A

Beta-blockers may mask the warning signs of hypoglycemia (e.g., tachycardia) and decrease serum glucose levels even further (see hypoglycemia). Since sulfonylureas also increase the risk of hypoglycemia, the combination of these two substances should be avoided

26
Q

what are the indications of sufonylureus

A

Patients who are not overweight, do not consume alcohol, and adhere to a consistent dietary routine

27
Q

indications for Meglitinides

A

particularly suitable for patients with postprandial peaks in blood glucose levels, but overall rarely prescribed

28
Q

when should meglitinides be taken?

A

should be taken shortly before meals.